The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Scotlouie. I got the usual email notification in the morning but like you I missed it.
By the time I had blinked, it was all over. Not that I have any funds anyway so hey ho.
I agree with Miss Audi though. We can't complain too much, after all, they were in the low 30's not so long ago. and if you didn't or couldn't take them then, then you have no case to complain now. Besides, it could be a lot worse than 54p after the placing.
I can't afford to buy anymore and what I do have, I have had to mentally write off. That way if it does eventually all turn out well, as I'm sure it will ... eventually, then it's all a bonus.
GLA
I would and do fully agree with you Steve. They are indeed involved with some of the best cancer research establishments in the world. AN and the BOD are doing sterling work in obtaining industry approval for Parsortix. I also fully understand that the said approval is a major requirement when it comes to rolling it out to a wider and future audience. In the mean time there is an income to be had from Parsortix and its disposable cassettes within a market that they are currently allowed to sell it in. Now it might not be enough to put the company into profit but it would raise awareness and income is income after all. To have only 147 machines out in the real world and I suspect not all of those were actual sales, is a woefully small amount. Now my comments and those of Peeks may not be the most upbeat you have heard but given the level of frustration some of us long term holders are feeling, even the most ardent supporter must accept that they are fair. No one wants Angle to reach the big prize more than I. I just don�t want the ship to sink before it gets there and the more self-sustainable is it is while making that journey the better.
I have been, and still am, a long term holder of this company but the truth of the matter is, you can't really argue with what he is saying. I am staying with it now for all the wrong reasons so all the if's but's and maybe's don't matter to me anymore. But putting the financials to one side for a moment. The people I feel most disappointed for are the cancer sufferers who need the parsortix machine brought to market a lot more then I need the money. Time I think to cut the crap and get some serious marketing done.
I'm not sure if this has been put up before but it's worth a read if you have not seen it. My apologies if you have. https://labiotech.eu/liquid-biopsies-cancer-detection-review/
Two years ago, the big question being asked was �Does it actually work�. Two years and numerous reports, trials and published papers later and that question had been answered. So much so that when a paper such as todays is published its as if we have become blas� about it. As I said two years ago todays report would have added another 20, 30 or even 40 percent to the share price. Albeit in a short-term spike. One other consequence of having this question answered is that there should be no more freebies. We need the revenue in order to answer todays big question. Todays big question is �Will it ever be put into clinical use� and we all know what is required for that happen. My view is that with more positive news, reports, and trial data being published (Almost daily it seems) it is only a matter of time before the market wakes up to the fact that Parsortixs place in modern medicine will be, and is, a given. It is MHO and hope that they will come to this conclusion before the FDA makes it official. If or rather when the FDA does give it the seal of approval I would like to see the SP double from a starting point of 80, 90 or even a pound rather than the pathetic and unjustified price it is currently at. I know the above sounds like wishful thinking but I cannot see any justification for the current SP. Not even taking the resent dilution into account. Anyway thats my thinking on the subject and thats why I�m looking forward to discussing these and other topics with you Mrs BMW and other fellow investors at the AGM. Oh dear, looks like I went waffling on again .. sorry See you on the 31st.
Excellent summary Boomorbust, even for the second time of reading, thanks a lot. I also like your reply to Jonesey71�s rather negative but understandable RNS comment. The key to Angle�s and Parsortix success lays in the establishing of those protocols. Without those research labs and KOL establishing acceptable guidelines on how to extract and analyze the cells collected by the Parsortix machine then the clinical world of medicine and its governing bodies, will never accept it. This isn�t just another gadget where you launch it into the world with a fanfare of marketing techniques and a few glossy posters and videos. You telling the world what it can do and how well it can do it counts for nothing. Even if you are proving it to the world it still cuts no ice with these boys�s. It�s down to those trusted and established universities, hospitals and laboratories (KOL�s) to do the research and publish their findings. Only then will the clinical world of medicine and its governing bodies sit up and take notice. Only then will you make money from your gadget. So yes it is a drawn out, painful, frustrating and expensive process. But it�s that process that allows you to charge a premium and it�s also that process that protects you from completion. I could waffle on for ages on this subject but I think you get the gist and besides Boomorbust put�s much eloquently than me.
I too have have every faith AN. It's been a long wait to get to where we are now and it's not over yet but having stuck with it this long I'm not about to quit now. I share your dream. GLA PS ... I hope you have them all in an ISA account
Shirley ... I have no doubt that one day those kind of machine number will be out there. Unfortunately for us Angle or Parsortix will have been long sold off by then and we will never see any dividends from those kind of profits. Bear that in mind when the takeover bids start coming in.
Snark hunter.. Thanks for doing the maths properly. The figures you used, re slides per day and machine in operation, are as far as I now know correct. So ignoring the sales revenue, even when you deduct the 6 million annual running costs you still end up in profit. The point these sums make is that no matter how you add them up, 48 million seems very undervalued. It had always been my hope that the share price, just before FDA approval, would be up around the low to mid 70’s which thanks to the unexpected news from Barts this week may still be the case. ... Roll on next week ... GLA